Literature DB >> 33219537

Effect of the polyphenol-rich extract from Allium cepa on hyperlipidemic sprague-dawley rats.

Wenyi Li1, Chunyan Yang1, Xue Mei1, Rong Huang1, Shipeng Zhang1, Yuanyuan Tang1, Qiuhong Dong1, Chunyang Zhou1.   

Abstract

Allium cepa is used for the prevention and treatment of hyperlipidemia-related diseases such as atherosclerosis in the folk. This study was mainly aimed at investigating the effects of A. cepa extract (ACE) enriched in polyphenols on hyperlipidemia Sprague-Dawley (SD) experiment rat models. The levels of total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), malondialdehyde (MDA), and superoxide dismutase (SOD) activity in serum and liver were measured using ELISA kits. In addition, hematoxylin-eosin (HE) technique was used to observe the liver and the aortic arch pathology. Moreover, western blotting (WB) method was applied to analyze LDL receptor (LDLR) and 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase (HMGCR) in liver. As a result, quercetin (2.42 mg/g DW) and isoquercitrin (4.60 mg/g DW) were the main constituents of ACE using HPLC analysis. Furthermore, ACE reduced the levels of TC, TG, LDL-C, and MDA, and increased HDL levels and elevated SOD activity both in serum and liver in hyperlipidemic SD rats (p < .05). HE results showed that liver fat drops of the rats in ACE group were obviously decreased, and the lipid and foam cells of the aortic arch of the rats in ACE group were markedly ameliorated. WB results showed that ACE promoted the degradation of HMGCR and increased LDLR expression in liver (p < .05). In conclusion, ACE alleviated hyperlipidemia with downregulation of HMGCR and upregulation of LDLR. PRACTICAL APPLICATIONS: Atherosclerosis, a major cardiovascular disease, is the leading cause of mortality and morbidity in the developed countries. Moreover, accumulating data indicate that, during atherosclerosis development, hyperlipidemia is an important risk factor. To date, hyperlipidemia is mainly treated with hyperlipidemic agents including statins, in spite of the side effects and poor tolerance in some patients. In addition, Allium cepa is a medicinal and edible plant. Furthermore, A. cepa is used for the prevention and treatment of hyperlipidemia-related diseases such as atherosclerosis in the folk. But the underlying mechanism is still unclear. In fact, this research showed that A. cepa extract (ACE) alleviated hyperlipidemia with downregulation of HMGCR and upregulation of LDLR, suggesting that ACE might be a potential option for hyperlipidemia as non-statin lipid-lowering agent.
© 2020 Wiley Periodicals LLC.

Entities:  

Keywords:  zzm321990Allium cepazzm321990; 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase; LDL receptor; anti-hyperlipidemia

Year:  2020        PMID: 33219537     DOI: 10.1111/jfbc.13565

Source DB:  PubMed          Journal:  J Food Biochem        ISSN: 0145-8884            Impact factor:   2.720


  4 in total

Review 1.  The Impact of Flavonols on Cardiovascular Risk.

Authors:  Joanna Popiolek-Kalisz; Emilia Fornal
Journal:  Nutrients       Date:  2022-05-09       Impact factor: 6.706

Review 2.  Allium cepa: A Treasure of Bioactive Phytochemicals with Prospective Health Benefits.

Authors:  Arka Jyoti Chakraborty; Tanvir Mahtab Uddin; B M Redwan Matin Zidan; Saikat Mitra; Rajib Das; Firzan Nainu; Kuldeep Dhama; Arpita Roy; Md Jamal Hossain; Ameer Khusro; Talha Bin Emran
Journal:  Evid Based Complement Alternat Med       Date:  2022-01-18       Impact factor: 2.629

Review 3.  Targeting Cardiovascular Diseases by Flavonols: An Update.

Authors:  Aleksandra Kozłowska; Dorota Szostak-Węgierek
Journal:  Nutrients       Date:  2022-03-30       Impact factor: 5.717

Review 4.  Natural Products in Cardiovascular Diseases: The Potential of Plants from the Allioideae Subfamily (Ex-Alliaceae Family) and Their Sulphur-Containing Compounds.

Authors:  Jorge M Alves-Silva; Mónica Zuzarte; Henrique Girão; Lígia Salgueiro
Journal:  Plants (Basel)       Date:  2022-07-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.